Výsledky vyhledávání - "cardiac myosin activator"

Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care

Autor: Daniela Tomasoni, Julie K.K. Vishram‐Nielsen, Matteo Pagnesi, Marianna Adamo, Carlo Mario Lombardi, Finn Gustafsson, Marco Metra

Publikováno v: Tomasoni, D, Vishram-Nielsen, J K K, Pagnesi, M, Adamo, M, Lombardi, C M, Gustafsson, F & Metra, M 2022, ' Advanced heart failure : guideline-directed medical therapy, diuretics, inotropes, and palliative care ', ESC heart failure, vol. 9, no. 3, pp. 1507-1523 . https://doi.org/10.1002/ehf2.13859

Heart failure (HF) is a major cause of mortality, hospitalizations, and reduced quality of life and a major burden for the healthcare system. The number of patients that progress to an advanced stage of HF is growing. Only a limited proportion of the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::074775ad683c3990026de8ec7c9a7292
https://pubmed.ncbi.nlm.nih.gov/35352499

Zobrazit plný text záznamu

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials

Autor: Alexandra Arias-Mendoza, Felix J. A. Ramires, Karen Sliwa, Tor Biering-Sørensen, Vyacheslav Mareev, Pranas Šerpytis, Rafael Diaz, Jonathan G. Howlett, Assen Goudev, Eileen O'Meara, Cândida Fonseca, Christopher E. Kurtz, Scott D. Solomon, Kirkwood F. Adams, Eva Goncalvesova, Luis E. Echeverría Correa, Diana Bonderman, John R. Teerlink, Michael Böhm, M. Lund, Galactic-Hf Investigators, Fady I. Malik, Jason C. Legg, María G. Crespo-Leiro, Ulf Dahlström, Lucie Sharpsten, Alexander Parkhomenko, Piotr Ponikowski, Peter S. Macdonald, James C. Fang, Ramón Corbalán, Thomas M. Suter, Mehmet Yilmaz, Gerasimos Filippatos, Jindrich Spinar, Hans Vandekerckhove, Shin-ichi Momomura, Faiez Zannad, János Tomcsányi, Adriaan A. Voors, G. Michael Felker, Inder S. Anand, John J.V. McMurray, Siddique Abbasi, Dragos Vinereanu, David E Lanfear, Claire Varin, John G.F. Cleland, Marco Metra

Publikováno v: European Journal of Heart Failure, 22(11), 2160-2171. Wiley
Teerlink, J R, Diaz, R, Felker, G M, McMurray, J J V, Metra, M, Solomon, S D, Adams, K F, Anand, I, Arias-Mendoza, A, Biering-Sorensen, T, Bohm, M, Bonderman, D, Cleland, J G F, Corbalan, R, Crespo-Leiro, M G, Dahlstrom, U, Echeverria Correa, L E, Fang, J C, Filippatos, G, Fonseca, C, Goncalvesova, E, Goudev, A R, Howlett, J G, Lanfear, D E, Lund, M, Macdonald, P, Mareev, V, Momomura, S, O'Meara, E, Parkhomenko, A, Ponikowski, P, Ramires, F J A, Serpytis, P, Sliwa, K, Spinar, J, Suter, T M, Tomcsanyi, J, Vandekerckhove, H, Vinereanu, D, Voors, A A, Yilmaz, M B, Zannad, F, Sharpsten, L, Legg, J C, Abbasi, S A, Varin, C, Malik, F I, Kurtz, C E & GALACTIC HF Investigators 2020, ' Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction : GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials ', European Journal of Heart Failure, vol. 22, no. 11, pp. 2160-2171 . https://doi.org/10.1002/ejhf.2015
Eur J Heart Fail
European journal of heart failure, Hoboken : John Wiley and Sons Ltd, 2020, vol. 22, iss. 11, p. 2160-2171
European Journal of Heart Failure
European Journal of Heart Failure, 2020, 22 (11), pp.2160-2171. ⟨10.1002/ejhf.2015⟩
RUC: Repositorio da Universidade da Coruña
Universidade da Coruña (UDC)
RUC. Repositorio da Universidade da Coruña
instname

Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested in the Global Approach to Lowering Adverse Cardiac outcomes Throug

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f000e290f8ad64a47f31d4c9a07593e9
https://research.rug.nl/en/publications/1dc2cc6b-2c2d-4680-b6c8-a27ff9da2c76

Zobrazit plný text záznamu

Plný text ve formátu HTML

Vyhledávací nástroje:

Upřesnit hledání